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Rawi Ramautar1,2, Ruud Berger1,2, Jan van der Greef1,2,3 and
Thomas Hankemeier1,2Metabolomics provides a direct functional read-out of the
physiological status of an organism and is in principle ideally
suited to describe someone’s health status. Whereas only a
limited number of small metabolites are used in the clinics, in
inborn errors of metabolism an extensive repertoire of
metabolites are used as biomarkers. We discuss that the
proper clinical phenotyping is crucial to find biomarkers and
obtain biological insights for multifactorial diseases. This
requires to study the phenotype dynamics including the
concepts of homeostasis and allostasis, that is, the ability to
adapt and cope with a challenge. We also elaborate that
biology-driven metabolomics platforms (i.e. development of
metabolomics technology driven by the need of studying and
answering important biomedical questions) addressing
clinically relevant pathways and at the same time providing
absolute concentrations are key to allow discovery and
validation of biomarkers across studies and labs. Following
individuals over years will require high throughput
metabolomics approaches, which are emerging for nuclear
magnetic resonance spectroscopy and direct-infusion mass
spectrometry, but should also include the biochemical
networks needed for personalized health monitoring.
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Introduction
Metabolomics is concerned with the comprehensive
analysis of low-molecular weight compounds in biological
samples such as cells, body fluids and tissues [1,2].
Metabolomics provides a direct functional read-out of§ This is an open-access article distributed under the terms of the Creative
which permits non-commercial use, distribution, and reproduction in any m
www.sciencedirect.comthe physiological status of an organism and is in principle
ideally suited to describe someone’s health status. Meta-
bolomics has the potential to deliver diagnostic bio-
markers for the detection and prognosis of diseases,
and the prediction of the efficacy and safety of pharma-
ceutical interventions [3–5]. Metabolomics can also pro-
vide insights into the biochemical mechanisms of diseases
and the modulation by drugs. It has become clear that
health and disease are optimally studied from a systems
perspective [6,7,8]. Only such an approach will allow a
personalized medicine approach, and system fingerprints
by metabolomics will play an important role in the future
to follow the health state of an individual [9]. At present,
there are still significant challenges in answering bio-
logical questions [10,11,12]. We will discuss these chal-
lenges and indicate possible directions of solutions.
Challenges in biomarker discovery with
metabolomics: characterization of the clinical
phenotype?
Considering the number of metabolites used in a clinical
setting as biomarkers of disease onset and/or progression,
the picture appears to be rather diverse. In the first place
in clinical chemistry a very limited number of small
metabolites such as glucose, cholesterol, creatinine, urea,
etc., is being used for decades to assess an individual’s
(pre-) disease condition. Secondly, in the field of inborn
errors of metabolism an extensive repertoire of metab-
olites is used as biomarkers for diagnosis, progression and
response to treatment [13]. Finally, in multifactorial
disorders like type 2 diabetes, metabolic syndrome or
neurodegenerative disorders there is an urgent need for
all types of biomarkers. Especially in this area of pathol-
ogy metabolomics is in principle very well suited to
identify and deliver biomarkers for clinical use. In general
‘omics’ technologies such as proteomics and genomics
have hardly contributed to obtain clinically useful and
accepted biomarkers, despite the vast number of papers
(more than 150 000) published on this subject [12].
Many of these omics-studies are hampered by the fact
that studies were not well designed, findings not vali-
dated in independent replica cohorts, but most important
no proper clinical phenotyping is available. The latter is
in contrast to the field of inborn errors of metabolism,
where the cause is always monogenetic and the resulting
clinical phenotypes extreme such as is the case in ami-
noacidopathies, organic acidurias or fatty acid oxidationCommons Attribution-NonCommercial-No Derivative Works License,
edium, provided the original author and source are credited.
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Figure 1
Illustration of dynamic system regulation. A system that is able to respond effectively to a challenge (‘allostasis’ area in the figure) can be called
‘healthy.’ When the system is no longer able to respond sufficiently, a disease state develops.
Figure taken from Ref. [9].disorders. In multifactorial diseases, the phenotype is
more complex, as various genetic and environmental
factors are involved, and the phenotype is probably highly
dynamic as well. At present the clinical characterization is
at a high generic level and consequently inclusion/exclu-
sion criteria will encompass several subtypes. Biomarkers
found from those studies can typically not be validated as
the subgroup diversity will be different in the next study.
This situation is probably better for drug-response bio-
markers.
The newer definitions of health and disease emphasizes
more a person’s ability to adapt and cope in the face of
social, physical and emotional challenges than describing
it as a state [14]. As a consequence a person’s phenotype is
considered dynamic and resilience becomes a key
parameter. Resilience is best evaluated during a system
response, so challenge-tests will becomemore common in
metabolomics research [9]. A classic example is the oral
glucose tolerance test, but also high fat challenges, exer-
cise, stress or mixed diets are used. Phenotype dynamics
will differ between individuals, and concepts as homeo-
stasis and allostasis can be considered (Figure 1). How-
ever, a precise (dynamic) description of the clinical
phenotype is currently missing, which is of utmost
importance to guide the discovery of diagnostic and
mechanistic biochemical biomarkers. Another challenge
is that mostly body fluids such as blood and urine are
available, but most studied biochemical networks are at
the cellular level and not at the systems regulatory level.
Therefore, we need to address cross-compartmentCurrent Opinion in Chemical Biology 2013, 17:841–846communication and system organization more than only
the pathways within cells. We expect that with the proper
phenotyping/genotyping, metabolomics will play an
important role in systems diagnosis, with an emphasis
on following the changes over time of an individual [15],
and on a somewhat longer term on integrated interven-
tions and personalized wellness (Figure 2). The analytical
strategy needed to be developed for achieving this is
discussed below.
Size of the human metabolome and what part
to address?
In metabolomics the general tendency is to analyze as
many low-molecular weight compounds (less than
2000 Da) as possible in a given biological sample at a
certain point in time with the aim to obtain maximal
biochemical information. The most recent version of the
Human Metabolome Database contains 40 335 metab-
olite entries, of which a major part consists of lipids [16].
This number does not only include endogenous metab-
olites but also exogenous compounds originating from
nutrients, microbiota, drugs and other sources. However,
it is our opinion that this number is still an underestima-
tion of the actual size of the human metabolome. Despite
the fact that advanced analytical techniques like nuclear
magnetic resonance (NMR) spectroscopy and mass spec-
trometry (MS) hyphenated to gas chromatography (GC),
liquid chromatography (LC) and/or capillary electropho-
resis (CE) have become well-established tools for meta-
bolomics studies [17,18,19,20,21], they still can only
capture a part of the human metabolome and, therefore,www.sciencedirect.com
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Figure 2
Metabolomics will become an essential part of systems diagnosis strategies, and later in integrated interventions based on identification of
subtypes of disease. Ultimately, personalized health strategies will be based on an integrated view of an individual taking different types of
biochemical profiling, physiological or systemic read outs and psychological processes into account. Abbreviations: HRV, heart rate variability;
ECG, electrocardiography.provide inherently biased results. We expect that new
developments or further refinements of analytical
technologies, especially with regards to sensitivity, will
significantly increase the coverage of metabolites. For
example, the integration of in-capillary preconcentration
techniques with a low flow sheathless interface for CE–
MS enhances concentration sensitivity by over two orders
of magnitude as compared to CE–MS based on a coaxial
sheath-liquid interface, resulting in nanomolar detection
limits in urine and a threefold increase in detected
molecular features [22]. Other improvements emerging
are better and innovative fractionation schemes, use of
nanoLC approaches, new microfluidic enrichment or sep-
aration devices [23] and improvements in mass spectrom-
etry. Themajority of peaks observed in a biological sample
by global but sensitive mass spectrometry-based analytical
platforms are often still unknown as it is a highly challen-
ging and time-consuming procedure to identify them
[18,24]. We expect that recent improvements in metab-
olite identification/assignment software tools for a more
efficient annotation and structure elucidation of the thou-
sands of peaks typically obtained for a complex biological
sample will yield many new metabolites [25–29].
Although the general tendency is to analyze as many
metabolites as possible in a given biological sample with
the aim to obtain maximal biochemical information, thiswww.sciencedirect.comis not necessarily required in order to obtain insights into
biological problems. Actually, Christians et al. recently
suggested that screening for changes in selected meta-
bolic pathways using a set of validated and quantitative
analytical platforms would be more suited than a global
metabolic profiling approaches, in which many compu-
tational and chemometric steps are needed to relate
changes in metabolic profiles to biochemical pathways
[30]. The available biochemical information for a certain
disease is used efficiently in such a biology-driven
approach. The global metabolomics strategy and the
biology-driven approach are nicely exemplified in the
recent work of Hazen and co-workers [31,32]. A global
metabolomics analysis of plasma revealed a pathway in
both humans and mice linking microbiota metabolism of
dietary choline and phosphatidylcholine to cardiovascular
disease (CVD) pathogenesis [31]. It was found that
plasma levels of three metabolites of dietary phospha-
tidylcholine — choline, betaine and trimethylamine N-
oxide (TMAO) — are associated with increased risk of
CVD. In a follow-up study, the gut microbiota-dependent
metabolism of L-carnitine to produce TMAO in both
rodents and humans was examined using a biology-driven
approach [32]. Using stable isotope tracer studies in
humans and animal models, the authors demonstrated
a role for gut microbiota metabolism of L-carnitine in
atherosclerosis pathogenesis.Current Opinion in Chemical Biology 2013, 17:841–846
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Fromtheprevious section it is clear that the total number of
detectable yet identifiable compounds is extensive, indi-
cating that efficient sample pretreatment techniques com-
bined with complementary analytical platforms are
minimally required in order to cover a significant fraction
of the human metabolome [18]. The sample pretreat-
ment strategies used in metabolomics prior to separation
anddetection encompass solvent extraction, ultrafiltration,
solid-phase extractionand/orderivatization,whichcan lead
to wide variations in recovery with distinct metabolic
profiles measured for the same sample [33]. Optimization
of sample pretreatment for the analytical platforms is key
for obtaining reliable and representativemetabolic profiles
of biological samples [33,34,35]. Actually, extensive
sample preparation ismostly applied due to the limitations
of the analysis method such as the limited dynamic range
(up to 5 decades) of a mass spectrometer (whereas the
concentration range of metabolites is at least nine decades
[36,37]) and disturbances of the analysis by matrix com-
ponents in the samples. Therefore, for each metabolomics
study, the sample pretreatment step should be properly
evaluated: (stable-isotope) internal standards should be
used to evaluate the recovery and analytical performance
ofmetabolites [38,39,40]. For globalmetabolic profiling of
human serum, Want et al. evaluated fourteen procedures
commonly used for metabolite extraction and protein
removal and found that the most optimal results with
regard to metabolic coverage and repeatability were
obtained with methanol [41]. In another study, Bruce
et al. found that two choices of solvent compositions were
most optimal for this purpose, that is, methanol/ethanol
(1:1, v/v) and methanol/acetonitrile/acetone (1:1:1, v/v/v),
which illustrates that there is still no general consensus on
the optimal sample pretreatment procedure for human
serum/plasma metabolomics [42]. This is even more true
for the extraction of intracellular metabolites from human
cells/cell lines [34,43]. In biology-driven/targeted metabo-
lomics, sample pretreatment can be directed to themetab-
olites of interest, and internal standards or isotope-labeled
standards can be used for the reliable (absolute) quantifi-
cation ofmetabolites [40]. By combining targeted and non-
targeted NMR, GC–MS and LC–MS methods to identify
and quantify as many metabolites as possible, the group of
Dr.Wishart detected4229 identifiedmetabolites in human
serum, of which 1070 were glycerolipids and 2177 phos-
pholipids [36]. In our lab we combine often a global
profiling approach using LC–MS, CE–MS and GC–MS
covering carbon/energy metabolism, lipids, etc., and more
with biology-driven LC–MS/MS platforms for biogenic
amines, signaling lipids, hormones, inflammation, oxi-
dative, metabolic stress, etc.
The development of robust, sensitive, high-throughput
and low-cost analytical technologies is of pivotal import-
ance for metabolic phenotyping in longitudinal studies
with clinically relevant biochemical coverage. At present,Current Opinion in Chemical Biology 2013, 17:841–846NMR-based metabolomics can be performed in a fully
automated, reproducible, high-throughput and cost-
effective manner [44]. Although NMR can be con-
sidered very robust, the sensitivity and metabolic cover-
age of MS cannot be matched currently by NMR. Rapid
direct flow injection MS analysis is increasingly used for
targeted metabolomics or lipidomics based on prese-
lected multiple reaction monitoring (MRM) pairs and
isotope labeled internal standards using rapid direct flow
injection MS analysis [45]. Recent MS applications
demonstrate that progress is being made in this area,
indicating that in the near future, MS and NMR will
most likely be used as complementary technologies in
large-scale epidemiology studies [44,46].
When not reporting absolute concentrations but relatively
(to internal standards) quantified data of identified/uni-
dentified metabolites, as is often the case in global but
also still biology-driven platforms, it is crucial to use
pooled samples and/or internal standards as quality con-
trols and for correction of variations and possible biases in
the overall analytical procedure during studies [47,48].
However, to accelerate biological interpretation by com-
parison across studies and labs, and integration with other
omics or clinical data (Figure 2), availability of identities
and preferably the concentrations of the metabolites is
important. As the concentration is influenced by the
sample preparation procedure, availability of reference
samples is important.
To zoom into biochemical processes and pathways, and/or
to validate biochemical mechanisms and to translate
findings from cell systems to animals and to humans,
and vice versa, stable-isotope based metabolomics is an
emerging promising strategy [38,39,40].
The future of metabolomics for monitoring
personal health
For the discovery of biomarkers of disease risk epi-
demiological studies are typically used. Associations be-
tween metabolite profiles and clinical outcome,
increasingly also in combination with genetic data, suggest
relevant pathways for the onset or progression of a multi-
factorial disease.However, thesebiomarkers are not able to
predict the disease onset or progression of an individual.
For the discovery of metabolic fingerprints to predict
disease onset and progression or outcome of interventions
at an individual level, longitudinal studies are needed
based on monitoring individuals over a year or more. We
are convinced that understanding the dynamics during loss
of allostasis or (sudden) systemic changes will be crucial to
understand the underlying biological processes. As an
example the oral glucose tolerance test is the widely
expected approach to test for an early onset of diabetes
type 2. Whereas under unperturbed conditions no diag-
nostic conclusion could be obtained, studying the system
response revealed differences, and studying the responsewww.sciencedirect.com
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insights [49]. Drugs are an alternative to perturb biological
systems to study diseases and their modulation by drugs
[3].These longitudinal studies ask for innovative analytical
approaches allowing the analysis of thousands of samples at
a low price per sample most likely in the order of tenths of
Euro’s. Where NMR and direct-infusion mass spectrom-
etry are slowly reaching the desired throughput, they only
partially cover the biochemical networks needed for
personalized health monitoring. However, we foresee that
in the future new MS-based approaches including micro-
fluidic modules will emerge with the desired throughput
and biochemical coverage, and measuring absolute con-
centrations allowing to discover and validate biomarkers
within and across the growing metabolomics research
community. These metabolic fingerprints will become
an important part of a patient-centered personalized, pre-
dictive, preventive, and participatory health care system
(Figure 2).
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